Mirum director exercises options, sells 2,000 shares

Mirum Pharmaceuticals director Saira Ramasastry reported an option exercise and share sale.

Rhea-AI Filing Summary

Mirum Pharmaceuticals director Saira Ramasastry reported an option exercise and share sale. On February 13, 2026, she exercised stock options covering 2,000 shares of common stock at an exercise price of $23.51 per share, converting a derivative position into shares.

On the same day, she then sold 2,000 shares of common stock in an open-market transaction at a price of $102.09 per share, leaving 0 common shares owned directly after the sale and 6,000 stock options held directly. The filing states the sale occurred under a Rule 10b5-1 trading plan adopted on September 18, 2025, and notes that the stock option involved is fully vested.

Insider Trade Summary

Exercise and Sale: 2,000 shares ($157K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Ramasastry Saira

Role Director

Sold 2,000 shs ($204K)

Approx. gross sale proceeds $204K

Approx. exercise cost $47K

Approx. pre-tax spread $157K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	2,000	$0.00	$0.00
Exercise	Common Stock	2,000	$23.51	$47K
Sale	Common Stock	2,000	$102.09	$204K

Holdings After Transaction: Stock Option (right to buy) — 6,000 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025.
2. F2. The stock option is fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MIRM director Saira Ramasastry report on this Form 4?

She exercised options for 2,000 Mirum Pharmaceuticals shares at $23.51, then sold 2,000 common shares at $102.09. After these trades, she directly held 0 common shares and 6,000 stock options that remain outstanding and fully vested.

At what prices did Saira Ramasastry exercise and sell Mirum Pharmaceuticals (MIRM) shares?

She exercised stock options at an exercise price of $23.51 per share and sold 2,000 Mirum Pharmaceuticals common shares at $102.09 per share. These transactions both occurred on February 13, 2026, as disclosed in the Form 4 filing.

How many Mirum Pharmaceuticals (MIRM) shares does Saira Ramasastry own after the reported transactions?

Following the reported transactions, she directly owns 0 shares of Mirum Pharmaceuticals common stock. However, she continues to hold 6,000 stock options, which are derivative securities that give her the right to acquire additional common shares in the future.

Were the Mirum Pharmaceuticals (MIRM) insider sales under a Rule 10b5-1 plan?

Yes. The Form 4 notes the sale occurred under a Rule 10b5-1 trading plan adopted on September 18, 2025. Such plans pre-schedule trades, allowing insiders to sell shares according to a predetermined program to help manage trading and compliance.

What type of derivative security did Saira Ramasastry exercise at Mirum Pharmaceuticals (MIRM)?

She exercised a stock option, described as a “Stock Option (right to buy)” with an exercise price of $23.51 per share. The underlying derivative covered 2,000 shares of common stock and is reported as fully vested with an expiration date of June 1, 2032.

What is the expiration date of the Mirum Pharmaceuticals (MIRM) stock options held by Saira Ramasastry?

The stock option referenced in the Form 4 expires on June 1, 2032. After exercising 2,000 option shares in this transaction, she continues to hold 6,000 options, which remain outstanding and fully vested according to the filing’s explanation of responses.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:38 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ramasastry Saira

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		M		2,000	A	$23.51	2,000	D
Common Stock	02/13/2026		S(1)		2,000	D	$102.09	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$23.51	02/13/2026		M			2,000	(2)	06/01/2032	Common Stock	2,000	$0	6,000	D

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025.

2. The stock option is fully vested.

	/s/ Judit Ryvkin, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.